Additionally, targeted molecular or gene therapy-based approaches directly targeting claudin-5 could pave the way for a new generation of drugs to treat epilepsy and other neurological conditions where BBB breakdown is a hallmark pathology. This evidence concerns the gene CLDN5 and epilepsy.